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Abstract 
Background: Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with 
vestibular schwannomas, meningiomas, and spinal ependymomas.  There have been anecdotal 
reports of radiographic response of spinal ependymomas in NF2 patients being treated for 
progressive vestibular schwannomas with bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor (VEGF).  
Aims: To review the clinical effects of bevacizumab treatment for symptomatic, NF2-associated 
ependymomas 
Methods: We conducted a retrospective review of all patients with NF2 treated with bevacizumab 
for symptomatic ependymoma at three NF2 specialty centers. Tumor size was evaluated by linear 
measurements; radiographic response was defined as >20% reduction in tumor size. We also 
performed immunohistochemical evaluation of NF2-associated symptomatic ependymomas from 
5 patients, including 2 from this clinical series.  
Results: Eight patients with NF2 and symptomatic ependymoma were treated with bevacizumab. 
All patients had subjective clinical improvement with bevacizumab, although only 5/8 patients 
evaluated had radiographic response. All tumors expressed VEGF-R2. 4/5 evaluated 
ependymomas expressed VEGF-R1; one without VEGF-R1 expression	was from a patient who 
showed clinical but not radiographic response.  
Conclusions: Treatment using bevacizumab improved symptoms related to NF2-associated 
ependymomas, often without concurrent radiographic response. This treatment effect may be 
related to VEGF-R1 expression in NF2-associated ependymoma.	
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Introduction 
  Neurofibromatosis type 2 (NF2) is a neurogenetic tumor predisposition disorder with an 
incidence of ~1:27,000. Hallmark lesions of NF2 include bilateral vestibular schwannomas, non-
vestibular schwannomas and meningiomas. In addition, an estimated 33% of patients with NF2 
have spinal ependymomas (4). Histopathology of these lesions includes tanycytic and 
myxopapillary (WHO grade 1) and classic (WHO grade 2) ependymoma; signs of anaplasia are 
uncommon (4;5). In contrast to their sporadic counterparts, ependymomas in NF2 appear almost 
exclusively in the spinal cord and are characterized by multi-segment tumor formation with large 
cystic compartments. 
 In most NF2 patients, spinal ependymomas are asymptomatic and therapy is not required; 
however, in about one-fourth of patients with ependymomas, tumors can cause significant 
neurological symptoms. Currently, the most common treatment for NF2-related symptomatic 
ependymomas is surgical resection. However, surgery has a high risk of spinal cord injury and 
perioperative complications, especially in patients exhibiting severe neurological symptoms such 
as paraparesis or sensory loss prior to surgery (4). For this reason, chemotherapeutic options for 
treatment are highly desirable. 
 Recent investigations have revealed potentially promising effects of bevacizumab on 
NF2-related vestibular schwannomas (9). Bevacizumab is a recombinant humanized monoclonal 
antibody against vascular endothelial growth factor (VEGF-A). Neutralization of VEGF may 
lead to inhibition of tumor growth, decreases in interstitial fluid pressure, and increased tumor 
oxygenation.  
 The effect of bevacizumab on ependymomas has not been established. In a small case 
series, 87.5% of adults with sporadic, recurrent ependymoma achieved either a partial response 
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or stable disease after treatment with bevacizumab (alone or in combination with cytotoxic 
chemotherapy) (11). However, in sporadic recurrent ependymoma in children, bevacizumab and 
irinotecan failed to show any sustained response (12). A report on the effect of bevacizumab in 
NF2 patients being treated for progressive vestibular schwannoma suggested an effect on spinal 
ependymomas (13), but to date, no studies have systematically addressed the response of 
symptomatic spinal ependymomas to bevacizumab in NF2. Here we report the clinical effect of 
bevacizumab on ependymomas in 8 patients with NF2, and VEGF receptor expression in 5 
resected, NF2-related ependymomas. 
 
Methods 
  All patients were diagnosed with NF2 by experienced clinicians based on consensus 
criteria.  Patients received bevacizumab as treatment for symptomatic ependymoma after 
consulting neurosurgeons deemed them poor candidates for surgery or they refused surgical 
treatment. Using MRIs of the head and spine performed with intravenous gadolinium contrast, 
we measured ependymoma size (in mm) using T2-weighted images with radiographic response 
was defined as ≥20% reduction in linear measures.  Volumetric assessment of ependymomas was 
not feasible due to the inhomogeneous appearance and cystic tumor formation.  We measured 
vestibular schwannoma volume (in cm3) using T1 post-contrast images, with radiographic 
response defined as ≥20% reduction in volume. Clinical and radiological follow up were 
performed routinely every 6 to 12 months.  
 
Immunohistochemistry: Three NF2-associated ependymomas from a case series previously 
reported by Hagel et al. (5) were available for immunohistochemical evaluation of VEGF-R1 and 
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VEGF-R2. In addition, pre-treatment surgical specimens from patients 3 and 5 of this case series 
were also analyzed for VEGF-R1 and R2. Immunohistochemical studies used four micrometer 
thick sections. Tissue sections were heat pre-treated followed by incubation with VEGFR-1 or 
VEGFR-2 antibodies (Santa Cruz sc-316, 1:100; Santa Cruz sc-504, 1:50) in an automated 
stainer (Ventana Medical Systems, Tucson, AZ, USA) according to standard protocols. Bound 
antibodies were detected by the peroxidase method using diaminobenzidine as chromogen (760-
500, Ultraview DAB, Ventana). All antibody reactions were validated prior to the study using 
isotype negative-controls and glioblastoma samples harboring pathological endothelial 
proliferations as positive controls (data not shown). 
 
3. Results  
 3.1 Patient characteristics: 8 patients (7 male, 1 female) from three institutions were 
treated with bevacizumab for symptomatic spinal ependymomas (Table 1). Median age at time of 
treatment was 22 years (range 15-34 years). Symptoms prompting treatment included dysphagia, 
ataxic gait, spastic paraparesis and intractable pain. Two patients underwent surgery prior to 
bevacizumab treatment (patient 3 and 5), with pathological confirmation of the diagnosis of 
ependymoma; for all other patients, diagnosis of ependymoma was made based on characteristic 
radiographic appearance.  Seven patients had radiographically documented ependymoma growth 
prior to treatment.  
 3.2 Bevacizumab treatment: The initial dose of bevacizumab was either 5 or 7.5 mg per 
kg every 2 weeks. In some patients, the dose was decreased during the course of treatment to 
minimize long term toxicity; four patients received 3.75 mg/kg every two weeks and four 
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patients received 7.5-10 mg/kg every three weeks.  The median duration of treatment was 13.5 
months (range 6-58 months).  
 3.3 Clinical and radiographic response: All eight patients had subjective improvement in 
neurologic function as rated both by the patient and the care team. Improved neurological 
symptoms included dysphagia (#1-2), sensory deficits (#3-8), weakness (#3-6), bladder and 
bowel dysfunction (#3), pain (#3, 6-8), and ataxia (#4-6).  
 Half of patients experienced radiographic response of ependymoma, seen within 3 to 6 
months after treatment initiation. In all four patients with a radiographic response (#4-7), the 
cystic compartments of the ependymoma demonstrated the greatest decrease in size. Importantly, 
there were no instances of pseudoresponse – the resolution of contrast enhancement – noted in 
any patients. (14) There was no obvious relationship between the degree of tumor shrinkage and 
perceived clinical benefit. For example, patient 3, who showed no significant radiographic 
change in tumor size, demonstrated improvement of ataxia, paraparesis and urinary incontinence 
such that he regained bladder control and ambulation.  
 3.4 Treatment breaks:  In 5/8 patients, treatment was held for ≥6 months. In three patients 
(#1,4,& 7), symptomatic improvements noted during treatment were lost during treatment hold, 
but returned within a few months when drug was re-started.  Radiographic progression was noted 
in patient 4 during treatment hold (Fig. 1), but was followed by a reduction of tumor size to the 
baseline volume after restarting bevacizumab. After stopping treatment, patient 2 and 8 presented 
with radiological relapse and increasing back pain.   
 3.5 Toxicity: Toxicity related to bevacizumab treatment was mild. One patient had a 
single episode of abdominal pain with hematochezia for which bevacizumab was held for 2 
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months. Symptoms improved, work-up was negative, and he was able to resume drug without 
complication. There were no grade 3 or 4 adverse events related to bevacizumab.  
 3.6 Immunohistochemistry: Upon immunohistochemical investigation, all tumors 
investigated showed expression of VEGF-R2 in all parts of the tumor (Fig. 2). 4/5 tumors 
showed expression of VEGFR-1 in tumor cells, and in 2/5 cases, the receptor was detected in 
endothelial cells. Staining ranged from scattered single cells over patchy expression to strong 
labeling of large tumor areas (Fig. 3). In one case, (patient 3) the staining was negative. This 
patient experienced clinical improvement but no radiographic response.  
 
Discussion 
 This is the first case series to investigate the effect of bevacizumab on symptomatic spinal 
ependymomas in patients with NF2. All eight patients showed clinical improvement, despite 
significant neurological impairments at baseline. Continued treatment with bevacizumab was 
necessary to maintain neurological improvement. In our experience, clinical and radiographic 
improvement occurred within 3 to 6 months of treatment and clinical relapse occurred about 6 
months after treatment discontinuation. Interestingly, some individuals had discordant 
radiographic changes in vestibular schwannomas and ependymoma, pointing to the heterogeinity 
of NF2-related tumors. 
 Shrinkage of tumors was primarily noted in the cystic portions of ependymomas, 
suggesting that the primary effect of bevacizumab is on vascular permeability rather than on 
tumor cells. The clinical improvement after treatment onset may be explained by an anti-edema 
effect of bevacizumab. In previous studies on vestibular schwannoma treated with bevacizumab, 
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there was a correlation between tumor shrinkage and change in the apparent diffusion coefficient 
value, a radiological marker for edema (8).   
 We found a slight endothelial expression and strong tumor tissue expression of VEGFR-1 
in 4/5 NF2-associated spinal ependymomas. Our findings agree with that of  Chan et al. (15), 
who reported that 5/6 sporadic ependymomas investigated by in-situ-hybridization for VEGFR-1 
and VEGFR-2 expression had slight to strong expression of mRNA of both receptors. 
 From our case series, patient 3 showed no significant expression of VEGF-R1 prior to 
treatment, which could explain the lack of radiographic response in this patient. However, this 
patient still displayed significant clinical improvement despite the lack of tumor shrinkage. For 
this reason, we believe that clinical improvement, rather than radiographic response, should be 
used to assess the benefit of bevacizumab for patients with NF2. 
 Because of the small sample size, our data cannot be generalized to all NF2 patients with 
symptomatic spinal ependymomas. Ependymomas were evaluated by linear measures and not by 
volumetric measurement, so small changes in tumor size might not have been detected. The 
patients presented in this case series were selected for bevacizumab treatment due to severe 
symptoms associated with their spinal ependymomas; however, many NF2 patients with 
ependymomas have few or no clinical impairments, making drug treatment unnecessary.     
 Taken together, these findings suggest bevacizumab improves clinical symptoms related 
to NF2-related spinal ependymoma in selected patients, with a less robust effect on tumor size. 
Further investigation is warranted to study the mechanisms and potential benefit of bevacizumab 
as a novel option for treatment of symptomatic ependymomas in NF2 patients.    
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Table 1. Patient characteristics 
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1 m 22 6 dysphagia/airway cervical Yes 8 Yes 
7.5 
q3 
No No Yes 
2 m 15 14 dysphagia/airway cervical Unknown 11 Yes 
7.5 
q3 
No No Yes 
3 m 25 12 
spastic 
paraparesis1 
cervical Yes 24 No 5 q3 Yes No2 Yes 
4 m 22 17 ataxic gait1 cervical Yes 36 Yes 5 q3 Yes Yes Yes 
5 f 34 23 
ataxic gait/ 
paraparesis1 
cervical 
and 
thoracic 
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6 m 34 27 ataxic gait1 cervical Yes 6 No 5 q2 Yes Yes Yes 
7 m 15 3 pain cervical Yes 58 Yes 5 q2 No Yes Yes 
8 m 20 10 pain cervical Yes 16 Yes 5 q2 Yes No Yes 
m: male, f: female, q3: every three weeks, q2: every two weeks 
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1 In addition to symptomatic ependymoma, patient also had progressive vestibular schwannoma. 
2Imunnohistochemical staining of pre-treatment surgical specimen revealed the ependymoma was negative for VEGFR-1 and positive 
for VERGFR-2. 
3Imunnohistochemical staining of pre-treatment surgical specimen revealed the ependymoma was positive for both VEGFR-1 and 
VEGFR-2. 
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Fig. 1: Spinal ependymoma (SE) in the cervical cord with a large cystic compartment (cy) of patient 4, shown with T2-weighted 
sagittal MRI (Siemens Avanto 1.5T). 
 
A) Before treatment with bevacizumab. B) After 6 months of treatment. C) 6 month after discontinuation of treatment. D) After re-
treatment.  
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Fig. 2: Immunohistochemical demonstration of VEGFR2 in spinal ependymoma of NF2 patients. 
 
Varying expression of VEGF-R2 in three samples of NF2-associated ependymomas, both in the vasculature and the tumor tissue. 
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Fig. 3: Immunohistochemical demonstration of VEGFR-1 expression in spinal ependymoma of NF2 patients. 
 
From left to right, tumor of patient 3, tumor of patient 5, three additional NF2-associated ependymomas from another case series; 
upper row, expression of VEGF-receptor in tumor endothelia; lower row, expression of VEGF-receptor in the tumor tissue; arrows 
indicate scattered positive cells. 
 
	
